A proportion of chronic hepatitis B patients with normal or only minimally elevated alanine aminotransferase (ALT) levels display significant histologic changes and would benefit from antiviral therapy. We aim to evaluate the histologic abnormalities seen in these patients and then determine which of them would most likely respond to peginterferon therapy. One hundred and thirteen hepatitis B e antigen (HBeAg)-positive patients with a normal or minimally elevated ALT level and moderate-to-severe histologic changes in their liver tissue were selected to receive peginterferon monotherapy and participate in a follow-up analysis. A multiple logistic regression analysis indicated that increasing age (P=.049) and lower hepatitis B virus (HBV) DNA levels (P=.038) were associated with significant histological abnormalities in patients with a normal or minimally elevated ALT.
Summary
A proportion of chronic hepatitis B patients with normal or only minimally elevated alanine aminotransferase (ALT) levels display significant histologic changes and would benefit from antiviral therapy. We aim to evaluate the histologic abnormalities seen in these patients and then determine which of them would most likely respond to peginterferon therapy. One hundred and thirteen hepatitis B e antigen (HBeAg)-positive patients with a normal or minimally elevated ALT level and moderate-to-severe histologic changes in their liver tissue were selected to receive peginterferon monotherapy and participate in a follow-up analysis. A multiple logistic regression analysis indicated that increasing age (P=.049) and lower hepatitis B virus (HBV) DNA levels (P=.038) were associated with significant histological abnormalities in patients with a normal or minimally elevated ALT.
Our predictive model which incorporated HBeAg testing at treatment week 12 combined with hepatitis B surface antigen (HBsAg) testing at treatment week 24 was able to identify which patients with a normal ALT level would achieve a sustained virological re- 90.0%). Lower HBsAg and HBeAg levels at treatment week 24 were associated with a SVR in patients with a minimally elevated ALT level (PPV: 100.0%, NPV: 100.0%). A liver biopsy and antiviral therapy should be strongly considered when treating HBeAg-positive patients with a normal or minimally elevated ALT level, low HBV DNA level, and aged >35 years. On-treatment quantification of combined HBsAg and HBeAg test results may be useful for predicting a SVR to peginterferon monotherapy in these patients.
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| INTRODUCTION
Chronic hepatitis B (CHB) remains a major health problem in China, and a persistent hepatitis B virus (HBV) infection can lead to severe liver disorders, such as liver cirrhosis, hepatic failure and hepatocellular carcinoma. 1 However, intervention with antiviral agents may prevent Due to its durable viral response and finite treatment course, peginterferon remains an important first-line treatment option for CHB. Because peginterferon functions as an immune mediator, high levels of ALT (two-to fivefold ULN) were determined to be an important pretreatment predictor of patient response in a previous study, 8, 9 and twofold ULN for ALT suggested as a reasonable threshold for initiating therapy even without liver biopsy. 6, 10, 11 While another published report found 20% of patients with lower ALT levels, < twofold ULN would achieve a sustained response to treatment 12 . Furthermore, as a substantial proportion of such patients do have suffered significant liver damage, a single normal or only mildly increased ALT value might lead to an unnecessary delay in initiating antiviral therapy. However, the aforementioned studies do not describe methods for identifying which patients with a normal or minimally elevated ALT level would most likely benefit from peginterferon therapy.
The current study was performed to identify which CHB patients with a normal or minimally elevated ALT level should receive antiviral therapy and then investigate the efficacy of peginterferon in these patients. We also developed a robust model for use in predicting a successful outcome of antiviral therapy.
| PATIENTS AND METHODS

| Patient cohort
Between 2010 and 2014, a total of 416 adult CHB patients who had undergone a liver biopsy were recruited for this study at the 
| Data collection
The follow-up schedule for all patients was as follows: biochemical, serological, and virological parameters were regularly measured every 3 months at an outpatient clinic, HBV serology, including HBsAg, antiHBsAg, HBeAg, and anti-HBeAg testing. Serum HBsAg testing was performed using commercial kits (Abbott Laboratories; Lake Bluff, IL, USA). HBV DNA titres were quantified using the Taq-Man probe-
Shenzhen, China) with a lower detection limit of 500 copies/mL. A conversion factor (5.26) was used for converting copies/mL to IU/mL.
Liver biochemistry was determined at each visit with a routine automated analysis system (Beckman Coulter; Fullerton, CA, USA). HBV genotyping was performed using the PCR-restriction fragment length polymorphism method. The patients were checked for drug compliance and clinical adverse events during each follow-up visit.
| Liver histology assessments
All liver biopsy specimens were reviewed by experts in gastroenterological pathology who were blinded to the patients' biochemical and virological results. The degrees of liver necroinflammation and fibrosis
were assessed according to criteria used in the Knodell scoring system.
Knodell necroinflammatory scores were divided into four categories:
minimal (0-3), mild (4-6), moderate (7-9) and severe (10-14) chronic hepatitis. The Knodell fibrosis scores were staged into four categories: minimal (0), mild (1), moderate (2-3), and severe (4). Moderate and severe scores were considered as reasons for starting treatment. 
| Statistical analyses
| RESULTS
| Baseline characteristics of patients
Among the 416 screened CHB patients, 23 patients were excluded; therefore, the results from 393 patients were included in our final analysis. Details of the included and excluded patients are shown in Figure 1 . One hundred and thirteen of the eligible patients (28.75%) had significant liver inflammation, and 78 (19.85%) had significant fibrosis. The patients with significant liver inflammation were an average of 5 years older than the patients with mild liver inflammation.
The sex, genotype, HBsAg results, HBeAg results, HBV DNA levels and ALT levels of the patients were similar, regardless of whether they showed inflammatory changes. Patients with severe fibrosis had lower HBeAg and HBV DNA levels than patients with mild fibrosis (Table 1) .
| Parameters associated with liver histological abnormalities
To select parameters which might predict histological abnormalities, multivariate analysis was performed using the following factors as they existed at baseline: age, gender, viral genotype, serum ALT, HBsAg, HBeAg and HBV DNA levels. Our analysis showed that among patients with a normal or minimally elevated ALT level, increasing age Significant histologic change n = 113
Normal ALT n = 57 was associated with significant necroinflammation, and lower HBV DNA levels were associated with significant fibrosis ( 
| Prediction of a SVR for patients stratified by ALT
Receiver operating characteristic curves were generated from our univariate and multivariate analyses of serum biomarkers and histological changes to evaluate the predictive values of these variables for a SVR in CHB patients with normal or minimally elevated ALT levels.
Among patients with a normal ALT level, the AUC for HBeAg at week OR, odds ratio; CI, confidence interval; ALT, alanine aminotransferase; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen.
T A B L E 4 Multivariate analysis of baseline and on-treatment factors associated with a SVR F I G U R E 2 Flow chart illustrating the use of an HBeAg level of 1.54 log 10 PEIU/mL at week 12 combined with an HBsAg level of 3.40 log 10 IU/mL at week 24 (A) among patients with a normal ALT level and an HBsAg level of 2.15 log 10 IU/mL combined with an HBeAg level of 1.32 log 10 PEIU/mL at week 24; (B) among patients with a minimally elevated ALT level to predict a sustained response at week 96 combined HBsAg and HBeAg AUC at week 24 for predicting a SVR was 0.90. When using a cut-off value of 1.43 log 10 PEIU/mL (25 PEIU/ mL), the sensitivity, specificity, positive predictive value, and negative predictive value of HBeAg for predicting a SVR was 88.9, 63.6%, 45.5%, and 88.0%, respectively. In this regard, the HBsAg value of 2.15 log 10 IU/mL when used in combination with an HBeAg value of 1.32 log 10 PEIU/mL had a sensitivity of 83.3%, specificity of 90.9%, positive predictive value of 100% and negative predictive value of 100% (Figure 2) , and was therefore better at predicting a SVR than was either the HBeAg or HBsAg value by itself.
| DISCUSSION
Previous investigations have demonstrated that HBeAg-positive patients with normal ALT levels usually display no or only minimal histologic evidence of progressive liver disease 13 ; thus, antiviral treatment is not usually recommended for these patients. 10 However, in our study, we found that 28.75% of CHB patients with normal or minimally elevated ALT levels had a significant liver inflammation score, and 19.85% had fibrosis >stage 2. This finding is similar to that in another study from Hong Kong, which found that an elevated ALT does not accurately predict significant liver injury. 14 Additionally, Liao 5 reported that significant fibrosis is not rare among patients with slightly increased ALT levels. 5 Thus, our findings suggest that decisions on whether to initiate antiviral therapy should not be heavily based on a particular ALT threshold. Furthermore, our results showed that being older than 35 years of age and having an HBV DNA load <3.94 log 10 IU/mL was strongly predictive of significant necroinflammation and fibrosis, respectively. These results highlight the need to perform a liver biopsy and make a treatment decision for older CHB patients who have normal or minimally elevated ALT levels and low levels of HBV DNA. Another report 12 recommended performing a liver biopsy when evaluating HBeAg-negative CHB patients >30 years of age and with an HBV DNA level ≥10 4 copies/mL, regardless of their ALT level.
We also examined various factors that were associated with the long-term clinical outcome of CHB patients with normal and minimally elevated ALT levels. In 1977, a study reported that HBeAg levels were strongly correlated with hepatitis B viral loads. 15 Decreased HBeAg levels eventually resulted in reduced HBV DNA replication, and thus, HBeAg seroconversion was considered as a turning point for predicting the efficacy of antiviral therapy. 16 Our results also showed that HBeAg levels decreased more significantly at treatment weeks 12 and 24 among patients who ultimately achieved a SVR, when compared with patients who did not achieve a SVR. However, some evidence also sug- Although our results suggest a promising new strategy for evaluating patients with normal or minimally elevated ALT levels, they still have several limitations. First, the CHB patients who had normal or minimally elevated ALT levels and received antiviral therapy were strictly selected according to specified guidelines; therefore, the number of enrolled patients was relatively small. Second, because the study had a retrospective design, the patient selection process may have been affected by referral bias. Larger well-designed studies are needed to validate our findings.
In summary, a reliance on increased ALT levels underestimates the true proportion of HBeAg-positive patients with normal or only minimally elevated ALT levels who have significant abnormalities in their liver tissue that would only be detected by a histologic examination. This supports the case for performing histologic assessments of liver damage in these patients and especially when evaluating patients of older age and with low HBV DNA levels. The combined use of HBsAg and HBeAg concentrations at 24 weeks of treatment with peginterferon can help physicians to make optimal treatment decisions for this special patient population.
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